A decade of immune-checkpoint inhibitors in cancer therapy

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: Role as a promising approach

Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9

Exploring Metabolic and Immunological Biomarkers for Oral Squamous Cell Carcinoma: Potential Targets for Precision Therapy

Rajneesh, Tiwari, R., Singh, V. K., Kumar, A., Mehrotra, S., Gautam, V., Neville, J. F., Bansal, V., Pathak, R., Singh, A. K., et al. (2025) · Biology · doi:10.3390/biology14091109 · Cited by 10

Overcoming cancer immunotherapy barriers via nanomaterial-mediated pyroptosis

Xie, J., Peng, B., Xiao, Y., Chen, X., Zhang, X., Chen, D., Song, L., Xu, M., Liao, W., & Zhang, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01024a · Cited by 10

Lactate metabolism and protein lactylation in cancer

Liu, Z., Li, A., Ma, Z., Wang, J., Chen, X., Wang, Z., & Fu, R. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00417-4 · Cited by 9

Metagenomics studies for the diagnosis and treatment of prostate cancer

Zarei, A., Javid, H., Sanjarian, S., Senemar, S., & Zarei, H. (2021) · The Prostate · doi:10.1002/pros.24276 · Cited by 9

Ezrin Regulates the Cell Surface Localization of PD-L1 in HEC-151 Cells

Tanaka, C., Kobori, T., Okada, R., Doukuni, R., Tameishi, M., Urashima, Y., Ito, T., Takagaki, N., & Obata, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082226 · Cited by 9

Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions

Liu, Z., Han, Y., Dang, Q., Xu, H., Zhang, Y., Duo, M., Lv, J., Li, H., Kong, Y., & Han, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109173 · Cited by 9

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

Mathews, C. A., Lorusso, D., Coleman, R. L., Boklage, S., & Garside, J. (2022) · The Oncologist · doi:10.1093/oncolo/oyac188 · Cited by 9

Association Between Metastatic Melanoma Response to Checkpoint Inhibitor Therapy and Tumor-Infiltrating Lymphocyte Classification on Primary Cutaneous Melanoma Biopsies

Stephens, M., Aderbigbe, O., Xu, W., Karakousis, G. C., Ming, M. E., & Chu, E. Y. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.4959 · Cited by 10

Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings

Picasso, R., Cozzi, A., Picasso, V., Zaottini, F., Pistoia, F., Perissi, S., & Martinoli, C. (2023) · La radiologia medica · doi:10.1007/s11547-023-01598-6 · Cited by 9

Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy

Martin, N. T., Crupi, M. J. F., Taha, Z., Poutou, J., Whelan, J. T., Vallati, S., Petryk, J., Marius, R. M., Austin, B., Azad, T., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16050709 · Cited by 9

Effects of Nanosecond Pulsed Electric Field on Immune Checkpoint Receptors in Melanoma Cells

Sauer, N. J., Szlasa, W., Szewczyk, A., Novickij, V., Saczko, J., Baczyńska, D., Daczewska, M., & Kulbacka, J. (2023) · Pharmaceuticals · doi:10.3390/ph16101362 · Cited by 9

Biology-aware mutation-based deep learning for outcome prediction of cancer immunotherapy with immune checkpoint inhibitors

Liu, J., Islam, M. T., Sang, S., Qiu, L., & Xing, L. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00468-8 · Cited by 9

Improving nanochemoimmunotherapy efficacy by boosting “eat-me” signaling and downregulating “don't-eat-me” signaling with Ganoderma lucidum polysaccharide-based drug delivery

Pang, G., Wei, S., Zhao, J., & Wang, F. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb02118a · Cited by 9

Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy

Chai, F., Li, P., Liu, X., Zhou, Z., & Ren, H. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad070 · Cited by 9

The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab

Smith, K. E. R., Pritzl, S. L., Yu, W., Bāra, I., Thanarajasingam, G., Kaul, M. D., Williams, K. A., Dueck, A. C., & Mansfield, A. S. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100611 · Cited by 9

Univariable and multivariable Mendelian randomization study identified the key role of gut microbiota in immunotherapeutic toxicity

Liu, B., Liu, Z., Jiang, T., Gu, X., Yin, X., Cai, Z., Zou, X., Dai, L., & Zhang, B. (2024) · European journal of medical research · doi:10.1186/s40001-024-01741-7 · Cited by 12

TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer

Ahmed, J. (2024) · American Journal of Cancer Research · doi:10.62347/mqff6404 · Cited by 9

Gene electrotransfer of proinflammatory chemokines CCL5 and CCL17 as a novel approach of modifying cytokine expression profile in the tumor microenvironment

Bozic, T., Serša, G., Kranjc, S., Čemažar, M., & Markelc, B. (2021) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2021.107795 · Cited by 9

Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach

Lisini, D., Lettieri, S., Nava, S., Accordino, G., Frigerio, S., Bortolotto, C., Lancia, A., Filippi, A., Agustoni, F., Pandolfi, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169014 · Cited by 7

Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes

Graf, J. R., Forster, S., Bruehl, F. K., Banz, Y., Hallal, M., Brodard, J., Bacher, U., Allam, R., Schürch, C. M., & Bonadies, N. (2021) · Cancers · doi:10.3390/cancers13225712 · Cited by 9

Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?

Molfetta, S. D., Feola, T., Fanciulli, G., Florio, T., Colao, A., Faggiano, A., & NIKE Group (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041019 · Cited by 9

In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker

Helfen, A., Rieß, J., Fehler, O., Stölting, M., An, Z., Kocman, V., Schnepel, A., Geyer, C., Gerwing, M., Masthoff, M., et al. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100792 · Cited by 9

Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress

Ji, H., Wen, Z., Liu, B., Chen, H., Lin, Q., & Chen, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.995121 · Cited by 9

An individualized causal framework for learning intercellular communication networks that define microenvironments of individual tumors

Chen, X., Chen, L., Kürten, C. H. L., Jabbari, F., Vujanovic, L. N., Ding, Y., Lu, B., Lu, K., Kulkarni, A., Tabib, T., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010761 · Cited by 14

Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?

Vergote, I. B., Ray-Coquard, I. L., Lorusso, D., Oaknin, A., Cibula, D., & Gorp, T. V. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2179483 · Cited by 9

Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer

Kumari, R., Hosseini, E. S., Warrington, K. E., Milonas, T., & Payne, K. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108722 · Cited by 9

Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population

Khaki, A. R., Glisch, C., & Petrillo, L. A. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00397 · Cited by 9

Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework

Leete, J. C., Zager, M. G., Musante, C. J., Shtylla, B., & Qiao, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1056365 · Cited by 8

Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis

Lee, E. E., Chen, X., LeCompte, M. C., Kleinberg, L. R., Hales, R. K., Voong, K. R., Forde, P. M., Brahmer, J. R., Markowski, M. C., Lipson, E. J., et al. (2023) · Journal of Neurosurgery Spine · doi:10.3171/2023.3.spine221086 · Cited by 8

Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction

Li, H., Sun, X., Zhao, Y., Zhang, C., Jiang, K., Ren, J., Xing, L., & He, M. (2023) · BMC Cancer · doi:10.1186/s12885-023-11015-w · Cited by 8

Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study

Masood, A. B., Batool, S., Bhatti, S. N., Ali, A., Valko, M., Jomová, K., & Kuča, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202098 · Cited by 8

Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer

Digomann, D., Heiduk, M., Reiche, C., Glück, J., Kahlert, C., Mirtschink, P., Klimová, A., Bösch, F., Tonn, T., Gaedcke, J., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00459-9 · Cited by 9

Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial

Zhang, C., Chen, J., Wu, H., Wang, J., Gao, L., Zhao, J., Sun, Y., Jia, Z., Mu, X., Bai, C., et al. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.02.001 · Cited by 8

SDCBP modulates tumor microenvironment, tumor progression and anti-PD1 efficacy in colorectal cancer

Yu, J., Yu, S., Bai, J., Zhu, Z., Gao, Y., & Li, Y. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00758-8 · Cited by 8

Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiency

Nguyen, M., Bonnin, D. A. A., Mirchia, K., Chen, W. C., Goldschmidt, E., Braunstein, S. E., Perry, A., Raleigh, D. R., & Bush, N. A. O. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae092 · Cited by 8

Long‐Term Storage Stable Vesicle‐Like Nanoparticles of Lipid and Polymer for siRNA and mRNA‐Mediated Cancer Immunotherapy

Chen, C., Zhang, Y., Cao, Z., Li, D., Zhu, Y., Jing, H., Li, Y., Li, F., Xu, C., Yang, X., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202406101 · Cited by 8

CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression

Rodrigues, J. M., Lokhande, L., Olsson, L. M., Hassan, M., Johansson, A., Janská, A., Kumar, D., Schmidt, L., Nikkarinen, A., Hollander, P., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012039 · Cited by 9

Host–Guest Interactions of Ruthenium(II) Arene Complexes with Cucurbit[7/8]uril

Roth, E. K. H., Listyarini, R. V., Hofer, T. S., & Cziferszky, M. (2024) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.4c01755 · Cited by 8

Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project

Rizzo, A., Monteiro, F. S. M., Ürün, Y., Massari, F., Park, S. H., Bourlon, M. T., Poprach, A., Rizzo, M., Takeshita, H., Giannatempo, P., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01089-2 · Cited by 8

Inhibition of Bruton’s tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors

Schwarz, E. J., Benner, B. N., Wesolowski, R., Quiroga, D. M., Good, L., Sun, S. H., Savardekar, H., Li, J., Jung, K. J., Duggan, M. C., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.169927 · Cited by 8

A comprehensive pan-cancer examination of transcription factor MAFF: Oncogenic potential, prognostic relevance, and immune landscape dynamics

Cai, F., Mao, S., Peng, S., Wang, Z., Li, W., Zhang, R., Zhang, S., Sun, A., & Zhang, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114105 · Cited by 8

Pretreatment nutritional indices are associated with survival and T-cell exhaustion in recurrent or metastatic oral squamous cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective cohort study

Ooyama, T., Hirayama, M., Seki, Y., Iwamoto, A., Yoshida, R., & Nakayama, H. (2025) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2025.01.010 · Cited by 8

Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients

Greib, A., Zhao, S., Ploch, M., Henricks, J., Easterling, R. S., Moodabagil, M., Lopez, G., Li, M., Goodyear, E. G., Sharp, J., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2469375 · Cited by 10

Identification of 5,7-Dihydro-6 H -pyrrolo[2,3- d ]pyrimidin-6-one Derivatives as ENPP1 Inhibitors for STING Pathway-Mediated Immunotherapy

Ji, S. H., Kang, M., Ahn, H., Baek, S. Y., Lee, I., Jeon, H., Chung, H. W., Han, D. K., Yang, S., Lee, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01021 · Cited by 8

Immune checkpoint inhibitor-associated diabetes mellitus: mechanisms, clinical manifestations, and management strategies

Chen, Y., Wang, X., & Duan, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1679751 · Cited by 9

MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance

González-Larreategui, Í., Martin, M. C., Casacuberta‐Serra, S., & Soucek, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738440 · Cited by 10

Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors

Yekedüz, E., Köksoy, E. B., Yazgan, S. C., Karataş, G., Şenler, F. Ç., Utkan, G., Akbulut, H., Demirkazık, A., & Ürün, Y. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001354 · Cited by 8

Cellular Membrane Localization of Innate Immune Checkpoint Molecule CD47 Is Regulated by Radixin in Human Pancreatic Ductal Adenocarcinoma Cells

Kobori, T., Ito, Y., Sawada, Y., Urashima, Y., Ito, T., & Obata, T. (2023) · Biomedicines · doi:10.3390/biomedicines11041117 · Cited by 8

Immune-related adverse events as independent prognostic factors for camrelizumab in patients with esophageal squamous cell carcinoma: a retrospective cohort study

Zhao, Y., Cong, D., Zhang, W., Jia, Y., & Bai, Y. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-75 · Cited by 8

Hepatoprotective effects of aspirin on diethylnitrosamine-induced hepatocellular carcinoma in rats by reducing inflammation levels and PD-L1 expression

Wang, Y., Wang, M., Liu, C., Hao, M., Wang, W., Li, Y., Shi, J., Zhang, X., & Dang, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-48812-z · Cited by 8

Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies

Augustin, R. C., Cai, W. L., Luke, J. J., & Bao, R. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2241 · Cited by 7

A novel ultrasensitive chemiluminescence enzyme immunoassay by employment of a signal enhancement of horseradish peroxidase-luminol-hydrogen peroxide reaction for the quantitation of atezolizumab, a monoclonal antibody used for cancer immunotherapy

Darwısh, I. A., Ali, M. A. H., Alsalhi, M. S., & Zhang, D. (2024) · RSC Advances · doi:10.1039/d4ra00202d · Cited by 8

Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis

Moodabagil, M., Easterling, R. S., Peng, J., Abu‐Sbeih, H., Meara, A. S., Donnelly, E. F., Owen, D. H., & Ho, K. (2024) · The Oncologist · doi:10.1093/oncolo/oyae147 · Cited by 8

Discovery and Evaluation of TLR-Targeted Immune Agonists

Chernyak, N., Bhagwat, B., Naravula, S., Chen, Y., Solban, N., Zhang, F., Kofman, E., Raoufi, F., Dang, X., Bao, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00804 · Cited by 8

Predicting and Monitoring Immune Checkpoint Inhibitor Therapy Using Artificial Intelligence in Pancreatic Cancer

Yu, G., Zhang, Z., Eresen, A., Hou, Q., Amirrad, F., Webster, S., Nauli, S. M., Yaghmai, V., & Zhang, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212038 · Cited by 8

Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy

Liu, J., Zhao, Z., Zanni, R., Jiang, X., Weichselbaum, R. R., & Lin, W. (2025) · ACS Nano · doi:10.1021/acsnano.4c16542 · Cited by 8

Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?

Ozaniak, A., Vachtenheim, J., Lischke, R., Bartůňková, J., & Strizova, Z. O. (2021) · Biomedicines · doi:10.3390/biomedicines9080935 · Cited by 8

Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis

Thakker, R. A., Lee, M. A., Albaeni, A., Elbadawi, A., Suthar, K. H., Perez, C., Sonstein, L. K., Farr, N. M., Venkatesan, R., Khalife, W. I., et al. (2021) · Cardiology Research · doi:10.14740/cr1319 · Cited by 9

Ezrin and Radixin Differentially Modulate Cell Surface Expression of Programmed Death Ligand-1 in Human Pancreatic Ductal Adenocarcinoma KP-2 Cells

Kobori, T., Doukuni, R., Ishikawa, H., Ito, Y., Okada, R., Tanaka, C., Tameishi, M., Urashima, Y., Ito, T., & Obata, T. (2022) · Immuno · doi:10.3390/immuno2010006 · Cited by 8

Bioinspired Membrane-Coated Nanoplatform for Targeted Tumor Immunotherapy

Mu, D., He, P., Shi, Y., Jiang, L., & Liu, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.819817 · Cited by 8

Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin

Nettersheim, F. S., Picard, F. S. R., Hoyer, F. F., & Winkels, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.812702 · Cited by 9

Administration of Immune Checkpoint Inhibitors Near the End of Life

Bloom, M. D., Saker, H., Glisch, C., Ramnaraign, B. H., George, T. J., Markham, M. J., & Kelkar, A. H. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00689 · Cited by 8

Updated Understanding of the Causes of Cancer, and a New Theoretical Perspective of Combinational Cancer Therapies, a Hypothesis

Muresanu, C., & Егорович, Х. С. (2022) · DNA and Cell Biology · doi:10.1089/dna.2021.1118 · Cited by 9

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning

Ward, K., Kitchen, M., Mathias, S.-J., Khanim, F. L., & Bryan, R. T. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.912438 · Cited by 8

Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis

Huo, G., Liu, W., Zhang, S., & Chen, P. (2023) · Immunotherapy · doi:10.2217/imt-2022-0140 · Cited by 9

Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors

Fatima, Z., Abonofal, A., & Stephen, B. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-27 · Cited by 9

Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells

van der Wulp, W., Gram, A. M., Bleijlevens, B., Hagedoorn, R. S., Araman, C., Kim, R. Q., Drijfhout, J. W., Parren, P. W. H. I., Hibbert, R. G., Hoeben, R. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183914 · Cited by 8

Multifunctional Nanoassembly for MRI-Trackable Dendritic Cell Dependent and Independent Photoimmunotherapy

Xiao, B., Xu, H., Xu, X., Pan, Y., Shi, X., Yuan, P., Slater, N. K. H., Sun, W., Tang, J., Shen, Y., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03098 · Cited by 8

The Association Between Albumin Levels and Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisPreprint

Güven, D. C., Şahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., & Yalçın, Ş. (2022) · Research Square · doi:10.21203/rs.3.rs-1785660/v1 · Cited by 8

IOBR2: Multidimensional Decoding Tumor Microenvironment for Immuno-Oncology ResearchPreprint

Zeng, D., Fang, Y., Luo, P., Qiu, W., Wang, S., Shen, R., Gu, W., Huang, X., Mao, Q., Lai, Y.-H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.13.575484 · Cited by 8

A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient

Lin, Y., Lin, Y., Zhong, X., Chen, Q., Tang, S., & Chen, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1280208 · Cited by 7

Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report

Fetter, T., Fietz, S., Bertlich, M., Braegelmann, C., de Vos‐Hillebrand, L., Wenzel, J., Heine, A., Landsberg, J., & Jansen, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1342845 · Cited by 7

Self-delivering RNAi immunotherapeutic PH-762 silences PD-1 to generate local and abscopal antitumor efficacy

Cuiffo, B., Maxwell, M., Yan, D., Guemiri, R., Boone, A., Bellet, D., Rivest, B., Cardia, J. P., Robert, C., & Fricker, S. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1501679 · Cited by 8

Roles of CDK12 mutations in PCa development and treatment

Jiang, C., Hong, Z., Liu, S., Hong, Z., & Dai, B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189247 · Cited by 8

Glycopolymeric Nanoparticles Block Breast Cancer Growth by Inhibiting Efferocytosis in the Tumor Microenvironment

Shofolawe-Bakare, O. T., Toragall, V. B., Hulugalla, K., Mayatt, R., Iammarino, P., Bentley, J. P., Smith, A. E., & Werfel, T. A. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c06534 · Cited by 7

Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: A comprehensive systematic review

Jayathilaka, B., Mian, F., Cockwill, J., Franchini, F., Au‐Yeung, G., & IJzerman, M. J. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104601 · Cited by 7

Immune Checkpoint Inhibitors Impact Fertility: A Review

Shabir, I., & Foster, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871340496250130054721 · Cited by 8

Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy

Enßle, S., Sax, A., May, P., Khawanky, N. E., Soliman, N., Perl, M., Enssle, J. C., Krey, K., Ruland, J., Pichlmair, A., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2504244 · Cited by 7

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Swanton, C., Madison, R. W., Tambaoan, C. F. B., Meric‐Bernstam, F., Sweeney, C. J., Kurzrock, R., Burris, H. A., Spigel, D. R., Tukachinsky, H., Hughes, J. D., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70054 · Cited by 7

Deciphering the MHC immunopeptidome of human cancers with Ligand.MHC atlas

Ran, Z., Mu, M., Lin, S., Wang, T., Zeng, J., Kuang, L., Chen, K., Suo, S., Yuan, K., & Xu, H. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf314 · Cited by 8

Research progress and future perspectives of prodrug strategies for immune checkpoint inhibitors in cancer immunotherapy

Li, T., Gao, S., Dong, D., Chen, Y., & Li, S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104905 · Cited by 7

Folate-modified liposomes for co-delivery of schisandrin A and oxaliplatin to enhance colorectal cancer cell death

Zhou, B., Dong, W., Fu, Y., & Jiang, Q. (2025) · Discover Oncology · doi:10.1007/s12672-025-03164-0 · Cited by 7

Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology

Stefanou, E., Tsitsinakis, G., Karageorgou, D., & Kole, C. (2025) · Cancers · doi:10.3390/cancers17172838 · Cited by 9

Cytotoxic CD4⁺ T cells exhibit an immunosuppressive shift in checkpoint immunotherapy resistance in melanoma patients

Bae, H. R., Son, B., Hwang, K., Kim, S., Young, H. A., & Kwon, E.-Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04145-6 · Cited by 7

Multifunctional hydrogels for synergistic therapy of cutaneous melanoma-associated tumor recurrence and wound regeneration

Li, M., Sun, Y., Hu, C., Luo, H., Li, M., & Yang, Y. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102331 · Cited by 7

Natural, Engineered, and Hybrid Platelet Membrane–Based Nanotherapeutics for Inflammatory Diseases

Liu, B., Wang, Y., Gong, W., Han, S., Lv, Z., Zhang, Z., Qi, J., Song, A., Yang, Z., Duan, L., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s558928 · Cited by 9

Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review

Torounidou, N., Yerolatsite, M., Bouratzis, V., Amylidi, A.-L., Zarkavelis, G., Naka, K. Κ., Voulgari, P. V., & Boussios, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311646 · Cited by 7

Inpatient utilization of immune checkpoint inhibitors and clinical outcomes

Wang, J., Lee, C., Attarian, S., Kohn, N. E., & Devoe, C. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221123967 · Cited by 7

Optimum Combination of Radiopharmaceuticals‐Based Targeting‐Triggering‐Therapy Effect and PD‐L1 Blockade Immunotherapy

Wen, X., Zeng, X., Shi, C., Liu, J., Zhang, Y., Shi, M., Li, J., Chen, H., Zhuang, R., Chen, X. S., et al. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200193 · Cited by 7

Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment

Han, J. K., Agarwal, A., Young, J. N., Owji, S., Luu, Y. T., Poplausky, D., Yassky, D., Estrada, Y. D., Ungar, J. P., Krueger, J. G., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-27020-1 · Cited by 7

The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

Güven, D. C., Özbek, D. A., Şahin, T. K., Kavgacı, G., Aksun, M. S., Erul, E., Yıldırım, H. Ç., Chalabiyev, E., Cebroyilov, C., Yıldırım, T., et al. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001463 · Cited by 7

Promises and challenges for targeting the immunological players in the tumor micro-environment – Critical determinants for NP-based therapy

Suresh, P. K., Banerjee, A., & Singh, P. (2023) · OpenNano · doi:10.1016/j.onano.2023.100134 · Cited by 7

Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma

Sener, U. T., Webb, M., Breen, W. G., Neth, B. J., Laack, N. N., Routman, D. M., Brown, P. D., Mahajan, A., Frechette, K. M., Dudek, A. Z., et al. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-20 · Cited by 7

Computational simulations of bispecific T cell engagers by a multiscale model

Su, Z., Almo, S. C., & Wu, Y. (2023) · Biophysical Journal · doi:10.1016/j.bpj.2023.12.012 · Cited by 7

Enabling continuous immune cell recirculation on a microfluidic array to study immunotherapeutic interactions in a recapitulated tumour microenvironment

Chi, C., Lao, Y., Ahmed, A. H. R., He, S., Merghoub, T., Leong, K. W., & Wang, S. (2024) · Lab on a Chip · doi:10.1039/d3lc00662j · Cited by 9

Immuno-Oncology Advances in Genitourinary Cancers

Zang, P. D., Angeles, A., Dorff, T. B., Pal, S. K., & Gupta, S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_430428 · Cited by 9

Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs. chemotherapy alone in HER2(–) locally advanced gastric cancer: A propensity score-matched cohort study

Xu, G., Liu, T., Shen, J., & Guan, Q. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003028 · Cited by 7

Ultrasound-triggered with ROS-responsive SN38 nanoparticle for enhanced combination cancer immunotherapy

Liu, H., Shi, Y., Ji, G., Wang, J., & Gai, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1339380 · Cited by 7

Navigating the tumor microenvironment: mesenchymal stem cell-mediated delivery of anticancer agents

Waqar, M. A., Zaman, M., Khan, R., Rahman, M. S. U., & Majeed, I. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2347356 · Cited by 7

["Immune checkpoint inhibitors in oncology"].

Daëron, M., & Vivier, É. (2021) · PubMed

Meditating on Cancer Management at the Time of Immunotherapy

Lopci, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113025

Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes

Weidhaas, J. B. (2022) · Immuno Oncology Insights · doi:10.18609/ioi.2022.030

Immunotherapy for cancer

Lee, A. J. X. (2022) · Medicine · doi:10.1016/j.mpmed.2022.10.007 · Cited by 3

Immuno-oncology: A changing paradigm in cancer therapy

Abdel-Rahman, O. M. (2016) · Advances in Modern Oncology Research · doi:10.18282/amor.v2.i6.187 · Cited by 1